Home›Trial›NCT04130997
🔬NCT04130997Phase 3ACTIVE NOT RECRUITING

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Study Summary

The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).

Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions / Drugs
Ublituximab
View on ClinicalTrials.gov ↗
Sponsor
TGTX
TG Therapeutics
Oncology
D36/100
Study Details
Enrollment1100 participants
Primary Completion—
Lead SponsorTG Therapeutics, Inc.
Data Retrieved2026-04-11 04:29:09.137956+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.